Drug Trial Radar · NCT03106779
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
Last checked: Nov 20, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
233
Actual
Start
Oct 26, 2017
Primary completion
May 25, 2020
Study completion Dec 4, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 10, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this pivotal study was to compare the efficacy of asciminib (ABL001) with that of bosutinib in the treatment of participants with chronic myeloid leukemia - chronic phase (CML-CP) having previously been treated with a minimum of two prior ATP-binding site tyrosine kinase inhibitors (TKIs).
Conditions
- Chronic Myelogenous Leukemia
Interventions
AsciminibDrug
40 mg tablets was taken orally twice a day (BID)
BosutinibDrug
500 mg tablets was taken orally once daily (QD)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major Molecular Response (MMR) Rate at 24 WeeksTime frame: 24 weeks
Locations
88 sites in 25 countries. Site status is shown where the registry gives one.
University of Chicago Hospital
Chicago, Illinois
Indiana Blood and Marrow Institute
Beech Grove, Indiana
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Dana Farber Cancer Center
Boston, Massachusetts
University of Michigan Clinical Trials Office
Ann Arbor, Michigan
Roswell Park Cancer Institute
Buffalo, New York
Weill Cornell Medicine NY-Presb
New York, New York
Memorial Sloan Kettering Cancer Ctr
New York, New York
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas
Utah Huntsman Cancer Center
Salt Lake City, Utah
Novartis Investigative Site
Capital Federal, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Adelaide, South Australia, Australia
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Murdoch, Western Australia, Australia
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Plovdiv, Bulgaria
Novartis Investigative Site
Varna, Bulgaria
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Brno, Czechia
Novartis Investigative Site
Ostrava, Poruba, Czechia
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Vandœuvre-lès-Nancy, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Heidelberg, Germany
Novartis Investigative Site
Kiel, Germany
Novartis Investigative Site
Mannheim, Baden-Wurttemberg, Germany
Novartis Investigative Site
Frankfurt am Main, Hesse, Germany
Novartis Investigative Site
Düsseldorf, North Rhine-Westphalia, Germany
Novartis Investigative Site
Jena, Thuringia, Germany
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Debrecen, Hajdu Bihar Megye, Hungary
Novartis Investigative Site
Jerusalem, Israel
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.